Drug Profile


Alternative Names: KD-019; KD-020; Tesevatinib tosylate; XL-647

Latest Information Update: 21 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Exelixis
  • Developer Exelixis; Kadmon Pharmaceuticals
  • Class Amines; Antineoplastics; Cyclopentanes; Pyrroles; Quinazolines; Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autosomal recessive polycystic kidney disease; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Autosomal dominant polycystic kidney disease; Glioblastoma
  • Phase I/II Breast cancer
  • Phase I Autosomal recessive polycystic kidney disease
  • No development reported Hepatocellular carcinoma; Prostate cancer

Most Recent Events

  • 09 Aug 2017 Kadmon Corporation initiates enrolment in a phase II trial for Autosomal-dominant polycystic kidney disease in USA (PO) (NCT03203642)
  • 08 Aug 2017 Tesevatinib receives Orphan Drug status for Non-small cell lung cancer in USA
  • 14 Jun 2017 Phase-I clinical trials in Autosomal-recessive polycystic kidney disease (In children) in USA (PO, suspension) (NCT03096080)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top